Kenneth W. Wall Buys 40,000 Shares of Bioamber Inc (BIOA) Stock

Bioamber Inc (NYSE:BIOA) Director Kenneth W. Wall acquired 40,000 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was bought at an average price of $0.43 per share, with a total value of $17,200.00. Following the transaction, the director now directly owns 170,443 shares in the company, valued at $73,290.49. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Bioamber Inc (NYSE BIOA) opened at $0.42 on Wednesday. Bioamber Inc has a 1 year low of $0.32 and a 1 year high of $6.24. The company has a current ratio of 1.08, a quick ratio of 0.75 and a debt-to-equity ratio of 0.24.

Several hedge funds have recently made changes to their positions in BIOA. Robecosam AG grew its holdings in shares of Bioamber by 82.9% in the 3rd quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock valued at $741,000 after buying an additional 670,000 shares during the period. TD Asset Management Inc. acquired a new position in shares of Bioamber in the 2nd quarter valued at $977,000. Bank of New York Mellon Corp grew its holdings in shares of Bioamber by 336.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 41,701 shares during the period. Vanguard Group Inc. grew its holdings in shares of Bioamber by 9.9% in the 2nd quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 27,278 shares during the period. Finally, FMR LLC grew its holdings in shares of Bioamber by 1.9% in the 2nd quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock valued at $3,495,000 after buying an additional 25,000 shares during the period. 29.97% of the stock is owned by institutional investors.

BIOA has been the subject of several research analyst reports. ValuEngine cut shares of Bioamber from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Bioamber in a research report on Wednesday, November 8th. Finally, Cowen reiterated a “hold” rating and set a $1.00 target price on shares of Bioamber in a research report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. Bioamber currently has an average rating of “Hold” and an average price target of $6.50.

ILLEGAL ACTIVITY WARNING: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://stocknewstimes.com/2017/12/06/kenneth-w-wall-buys-40000-shares-of-bioamber-inc-bioa-stock.html.

Bioamber Company Profile

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Receive News & Ratings for Bioamber Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply